ANDA 205695, held by Anbison Laboratory. Montelukast Sodium.
As of Nov 21, 2026, ANDA 205695 (Montelukast Sodium), held by Anbison Laboratory, was first approved by FDA on Nov 5, 2015, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 5, 2015 | Original application | Approved | None posted |
| Montelukast SodiumEQ 4MG BASE · tablet, chewable;oral | Montelukast Sodium | Rx |
| Montelukast SodiumEQ 5MG BASE · tablet, chewable;oral | Montelukast Sodium | Rx |
| Jun 28, 2023 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jun 28, 2023 | Supplement 4Labeling · Standard review | Approved | None posted |
| Nov 5, 2015 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters